Literature DB >> 33718205

Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma.

Wenkai Ni1,2, Saiyan Bian1,3, Mengqi Zhu3, Qianqian Song4, Jianping Zhang3, Mingbing Xiao3, Wenjie Zheng3.   

Abstract

PURPOSE: Ubiquitin-specific proteases (USPs), as a sub-family of deubiquitinating enzymes (DUBs), are responsible for the elimination of ubiquitin-triggered modification. USPs are recently correlated with various malignancies. However, the expression features and clinical significance of USPs have not been systematically investigated in hepatocellular carcinoma (HCC).
METHODS: Genomic alterations and expression profiles of USPs were investigated in CbioPortal and The Cancer Genome Atlas (TCGA) Liver hepatocellular carcinoma (LIHC) dataset. Cox regression and least absolute shrinkage and selection operator (LASSO) analyses were conducted to establish a risk signature for HCC prognosis in TCGA LIHC cohort. Subsequently, Kaplan-Meier analysis, receiver operating characteristic (ROC) curves and univariate/multivariate analyses were performed to evaluate the prognostic significance of the risk signature in TCGA LIHC and international cancer genome consortium (ICGC) cohorts. Furthermore, we explored the alterations of the signature genes during hepatocarcinogenesis and HCC progression in GSE89377. In addition, the expression feature of USP39 was further explored in HCC tissues by performing western blotting and immunohistochemistry.
RESULTS: Genomic alterations and overexpression of USPs were observed in HCC tissues. The consensus analysis indicated that the USPs-overexpressed sub-Cluster was correlated with aggressive characteristics and poor prognosis. Cox regression with LASSO algorithm identified a risk signature formed by eight USPs for HCC prognosis. High-risk group stratified by the signature score was correlated with advanced tumor stage and poor survival HCC patients in TCGA LIHC cohort. In addition, the 8-USPs based signature could also robustly predict overall survival of HCC patients in ICGC(LIRI-JP) cohort. Furthermore, gene sets enrichment analysis (GSEA) showed that the high-risk score was associated with tumor-related pathways. According to the observation in GSE89377, USP39 expression was dynamically increased with hepatocarcinogenesis and HCC progression. The overexpression of USP39 was further determined in a local HCC cohort and correlated with poor prognosis. The co-concurrence analysis suggested that USP39 might promote HCC by regulating cell-cycle- and proliferation- related genes.
CONCLUSION: The current study provided a USPs-based signature, highlighting its robust prognostic significance and targeted value for HCC treatment.
Copyright © 2021 Ni, Bian, Zhu, Song, Zhang, Xiao and Zheng.

Entities:  

Keywords:  hepatocellular carcinoma; molecular target; prognosis; risk signature; ubiquitin-specific proteases

Year:  2021        PMID: 33718205      PMCID: PMC7949004          DOI: 10.3389/fonc.2021.629327

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  29 in total

Review 1.  Ubiquitylation and cell signaling.

Authors:  Kaisa Haglund; Ivan Dikic
Journal:  EMBO J       Date:  2005-09-08       Impact factor: 11.598

2.  Knockdown of ubiquitin-specific peptidase 13 inhibits cell growth of hepatocellular carcinoma by reducing c-Myc expression.

Authors:  Jing Huang; Zhen-Lin Gu; Wei Chen; Ying-Ying Xu; Ming Chen
Journal:  Kaohsiung J Med Sci       Date:  2020-04-07       Impact factor: 2.744

3.  USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.

Authors:  Chang Lu; Zhen Ning; Aman Wang; Di Chen; Xiaolong Liu; Tian Xia; Dinesh Singh Tekcham; Wen Wang; Tongming Li; Xiumei Liu; Jing Liu; Huan Qi; Haifeng Luo; Jian Du; Chi Ma; Qiu Yan; Jiwei Liu; Guowang Xu; Hai-Long Piao; Guang Tan
Journal:  Cancer Lett       Date:  2018-07-26       Impact factor: 8.679

Review 4.  Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets.

Authors:  Dingding Shi; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

Review 5.  Breaking the chains: deubiquitylating enzyme specificity begets function.

Authors:  Michael J Clague; Sylvie Urbé; David Komander
Journal:  Nat Rev Mol Cell Biol       Date:  2019-06       Impact factor: 94.444

Review 6.  Mechanisms of Deubiquitinase Specificity and Regulation.

Authors:  Tycho E T Mevissen; David Komander
Journal:  Annu Rev Biochem       Date:  2017-05-12       Impact factor: 23.643

Review 7.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

8.  Clinical Significance of Ubiquitin Specific Protease 7 (USP7) in Predicting Prognosis of Hepatocellular Carcinoma and its Functional Mechanisms.

Authors:  Xujing Wang; Qiqi Zhang; Yongkun Wang; Huiren Zhuang; Bo Chen
Journal:  Med Sci Monit       Date:  2018-03-25

9.  Ubiquitin-specific protease 7 is a drug-able target that promotes hepatocellular carcinoma and chemoresistance.

Authors:  Wei Zhang; Jingxin Zhang; Chenzhou Xu; Shiqing Zhang; Saiyan Bian; Feng Jiang; Wenkai Ni; Lishuai Qu; Cuihua Lu; Runzhou Ni; Yihui Fan; Mingbing Xiao; Jinxia Liu
Journal:  Cancer Cell Int       Date:  2020-01-28       Impact factor: 5.722

Review 10.  Targeted therapy for hepatocellular carcinoma.

Authors:  Ao Huang; Xin-Rong Yang; Wen-Yuan Chung; Ashley R Dennison; Jian Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-08-11
View more
  4 in total

1.  High Expression of Ubiquitin-Specific Protease 39 and Its Roles in Prognosis in Patients with Hepatocellular Carcinoma.

Authors:  Yu Liao; Lin Li; Huabao Liu; Yi Song
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-27       Impact factor: 2.629

2.  Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.

Authors:  Jie Fu; Xiaohua Lei
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

3.  MiR-520a-5p/PPP5C regulation pattern is identified as the key to gemcitabine resistance in pancreatic cancer.

Authors:  Ruibiao Fu; Qian Shao; Bin Yang; Yan Chen; Qinghuang Ye; Xi Chen; Jinhui Zhu
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

4.  A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.

Authors:  Guanghao Li; Yongheng Liu; Yanting Zhang; Yao Xu; Jin Zhang; Xianfu Wei; Zhongmin Zhang; Chao Zhang; Jinyan Feng; Qiang Li; Guowen Wang
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.